Retinal Disease: ABBV-RGX‑314, being developed in collaboration with AbbVie ... at dose level 4 (1.5x10e12 GC/eye) with short course prophylactic steroid eye drops. ABBV-RGX-314 for the ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Bank stocks largely boosted the Dow, as investors hope the sector could see weaker regulation in a second Trump ...

The advantage of SLT over eye drops occurred despite ongoing treatment ... Lind disclosed relationships with AbbVie, Heru, Nicox, and SpyGlass. Source Reference: Montesano G, et al "Six-year ...

AbbVie (ABBV) lifted its full-year outlook on Wednesday as the biopharmaceutical company recorded better-than-expected third-quarter results amid robust sales of its Skyrizi and Rinvoq immunology ...

Higher mean blood pressure (BP) levels were associated with faster rates of visual field progression in patients with ...

Presbyopia is an age-related refractive condition marked by a gradual decline in near vision, typically emerging between ages 40 and 60. It results from the lens ...

Speaking at the 13D Monitor Active-Passive Investor Summit on Tuesday, Smith described Pfizer’s share price drop since the Covid pandemic as ... said trailed peers including Eli Lilly & Co. and AbbVie ...

AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...

their biggest intraday drop since March 2020. The stock had gained 29% this year through Friday’s close, outperforming a 26% rise in the S&P 500. “This outcome is a real dagger” for AbbVie ...

Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. Read why I continue to rate ...